Peter Traber
Direktor/Vorstandsmitglied bei Baylor College of Medicine
Vermögen: 110 791 $ am 30.04.2024
Profil
Dr. Peter G.
Traber, MD, is on the Board of Directors at Baylor College of Medicine.
Dr. Traber was previously employed as a Chief Medical Officer by Selecta Biosciences, Inc., a Partner by Alacrita Consulting Ltd., an Independent Director by Caladrius Biosciences, Inc., a President, Chief Executive & Medical Officer by Galectin Therapeutics, Inc., a Chief Medical Officer & SVP-Clinical Development by GlaxoSmithKline Plc, a Chief Medical Officer by Cartesian Therapeutics, Inc., a Chief Medical Officer by Morphic Therapeutic, Inc., a Chairman & Chief Executive Officer by Terrasep LLC, a Chief Executive Officer by The University of Pennsylvania Health System, and a Chairman-Internal Medicine Department by University of Pennsylvania Medical Center.
He also served on the board at Noble International Ltd.
and Tanox, Inc. He received his undergraduate degree from the University of Michigan and a doctorate degree from The Wayne State University School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
0,03% | 18.04.2024 | 5 301 ( 0,03% ) | 110 791 $ | 30.04.2024 |
Aktive Positionen von Peter Traber
| Unternehmen | Position | Beginn |
|---|---|---|
| Baylor College of Medicine | Direktor/Vorstandsmitglied | 01.01.2008 |
Ehemalige bekannte Positionen von Peter Traber
| Unternehmen | Position | Ende |
|---|---|---|
| CARTESIAN THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 13.11.2023 |
| Alacrita Consulting Ltd. | Corporate Officer/Principal | 01.08.2020 |
| GALECTIN THERAPEUTICS INC. | Vorstandsvorsitzender | 06.07.2018 |
Tanox, Inc.
 Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Direktor/Vorstandsmitglied | 03.08.2007 |
Ausbildung von Peter Traber
| University of Michigan | Undergraduate Degree |
| The Wayne State University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GALECTIN THERAPEUTICS INC. | Health Technology |
| GSK PLC | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Noble International Ltd.
 Noble International Ltd. Auto Parts: OEMProducer Manufacturing Noble International Ltd. manufactures and supplies automotive components, provides laser welding and cutting services. The company is headquartered in Troy, MI. | Producer Manufacturing |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Health Technology |
Selecta Biosciences, Inc.
 Selecta Biosciences, Inc. BiotechnologyHealth Technology Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA. | Health Technology |
The University of Pennsylvania Health System
 The University of Pennsylvania Health System Miscellaneous Commercial ServicesCommercial Services The University of Pennsylvania Health System provides general patient care as well as medical education and research services. The company was founded in 1874 and is headquartered in Philadelphia, PA. | Commercial Services |
Caladrius Biosciences, Inc.
 Caladrius Biosciences, Inc. BiotechnologyHealth Technology Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in development of cell therapies for select cardiovascular and autoimmune diseases. Its product pipeline includes XOWNA, CLBS12, CLBS201 and CLBS14. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ. | Health Technology |
| Terrasep LLC | |
Morphic Therapeutic, Inc.
 Morphic Therapeutic, Inc. BiotechnologyHealth Technology Morphic Therapeutic, Inc. engages in biotechnology drug development activity. The company is headquartered in Waltham, MA. | Health Technology |
| Alacrita Consulting Ltd. |
